Abstract
This chapter provides answers to practice-based questions with case studies covering the new principles of diagnosis, classification, staging, treatment, and outcomes in the rapidly advancing field of early-stage estrogen receptor (ER)/progesterone receptor–positive, HER2-negative breast cancer. Adjuvant endocrine therapy of early stage, hormone sensitive breast cancer continues to evolve with unanswered questions regarding the optimal duration of both tamoxifen and aromatase inhibitors as well as integration of newer targeted therapies for those with high risk disease. These questions remain germane because ER–positive breast cancer has an ongoing risk of recurrence 20 years after the original diagnosis, with a greater absolute risk for late recurrence especially for those with higher risk features at diagnosis.
Original language | English (US) |
---|---|
Title of host publication | Cancer Consult |
Subtitle of host publication | Expertise in Clinical Practice, Volume 1: Solid Tumors and Supportive Care |
Publisher | wiley |
Pages | 129-138 |
Number of pages | 10 |
Volume | 1 |
ISBN (Electronic) | 9781119823766 |
ISBN (Print) | 9781119823735 |
DOIs | |
State | Published - Jan 1 2023 |
Keywords
- Endocrine therapy
- ER–positive breast cancer
- HER2-negative breast cancer
- Hormone sensitive breast cancer
- Progesterone receptor–positive breast cancer
ASJC Scopus subject areas
- General Medicine